NOV 1, 2026 · REVIEW
Navigating the Challenges of Shared Decision‐Making in Amyloid Immunotherapy for Alzheimer's Disease
European Journal of Neurology
BACKGROUND: Anti-amyloid therapies (AATs), such as lecanemab and donanemab, represent a major therapeutic development for early Alzheimer's disease (AD). However, safety risks and